NovoCure Ltd NVCR
NovoCure Ltd (Nasdaq: NVCR) is an oncology medical device company. Its next catalyst on record is KEYNOTE D58: Completion of enrollment (Phase 3 GBM) (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: KEYNOTE D58 — Completion of enrollment (Phase 3 GBM) (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Optune Gio | Glioblastoma | device-combination | NA_NON_THERAPEUTIC |
| Optune Lua | Metastatic NSCLC; mesothelioma (HDE) | device-combination | NA_NON_THERAPEUTIC |
| Optune Pax | Locally advanced pancreatic cancer (FDA PMA Feb 2026) | device-combination | NA_NON_THERAPEUTIC |
| Optune Mya (METIS, PMA submitted Dec 2025) | Brain metastases from NSCLC | device-combination | NA_NON_THERAPEUTIC |
| KEYNOTE D58 (Phase 3) | Newly diagnosed GBM with temozolomide + pembrolizumab | device-combination | NA_NON_THERAPEUTIC |
| LUNAR-2 (Phase 3) | First-line metastatic NSCLC with pembrolizumab + chemo | device-combination | NA_NON_THERAPEUTIC |
| TRIDENT (Phase 3, did not meet primary endpoint) | Newly diagnosed GBM, early start | device-combination | NA_NON_THERAPEUTIC |
Recent results and decisions
- Oct 1, 2026approval Japan's Ministry of Health, Labour and Welfare approved Optune Pax for the treatment of unresectable locally advanced pancreatic cancer.
Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
Filing - Jun 18, 2026missed TRIDENT missed primary endpoint: median OS 17.7 vs 17.5 months, early-start vs maintenance-start TTFields (HR 0.953, p=0.519).
The trial did not demonstrate a statistically significant improvement in the primary endpoint of overall survival for the Early Start Arm compared to the Maintenance Start Arm.
Filing - Jan 12, 2026submitted Final module of PMA for TTFields in NSCLC brain metastases submitted December 2025; FDA decision expected Q4 2026.
In December, Novocure submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for TTFields therapy use for the treatment of brain metastases from NSCLC.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other oncology companies
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- Personalis, Inc. PSNL
- AnaptysBio, Inc. ANAB
- Freenome, Inc. FRNM
- Alpha Tau Medical Ltd. DRTS
- Castle Biosciences Inc CSTL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.